ReviewCurrent opinion in psychiatry2026
Clozapine treatment in the early stages of schizophrenia.
Review in Current opinion in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- When Doing Nothing Feels Safer: A Multilevel Framework for Therapeutic Inertia in Psychiatry.Healthcare (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewClozapine is the most effective treatment for antipsychotic nonresponse, yet its use in the early stages of schizophrenia remains substantially delayed. Because the first several years after diagnosis represent a critical window for influencing long-term outcomes, clarifying the benefits, risks, and implementation challenges of earlier clozapine initiation is both timely and clinically relevant. This review synthesizes recent evidence on clozapine effectiveness, safety, and utilization within the first five years of illness. RECENT
findingsAcross cohort studies, registry analyses, and meta-analyses, clozapine demonstrates superior response and relapse-prevention outcomes when used following early treatment failure or relapse. Sequential treatment data show diminishing returns with repeated nonclozapine antipsychotic trials, whereas clozapine maintains comparatively higher response rates. Earlier initiation, particularly within three years of first episode, is associated with improved negative symptoms and functioning. Despite these advantages, clozapine remains markedly underutilized, with substantial delays. Safety profiles in first episode and early-phase samples mirror established risks, with serious adverse events uncommon in the short term. SUMMARY: Evidence supports considering clozapine earlier in the treatment sequence for early-stage schizophrenia, particularly after initial nonresponse or relapse. System-level interventions and emerging biomarker-guided strategies may reduce delays and improve long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.